Company Profile

Genetic Therapy Inc (AKA: GTI)
Profile last edited on: 6/2/21      CAGE:       UEI:

Business Identifier: Therapies based on insertion of gene-modified cells into patient's body
Year Founded
1986
First Award
1989
Latest Award
1995
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

938 Clopper Road
Gaithersburg, MD 20878
   (301) 590-2626
   N/A
   N/A
Location: Single
Congr. District: 06
County: Montgomery

Public Profile

In December 1995, Genetic Therapy Inc (NASDAQ:GTII) was acquired by Sandoz Ltd (merged with Ciba-Geigt Ltd to become Novartis) - a firm with which there had been a long standing working relationship. GTI is an indirect wholly owned subsidiary of Novartis and is now established as the Novartis Center of Excellence for gene therapy. Organized fromtheoutset around bringing to market gene therapy products for the treatment of life-threatening genetic and acquired diseases, Genetic Therapy's novel approach involved insertion of genes into cells to produce therapeutic proteins in the body, or the genetic vectors themselves can destroy cells that are malignant (oncolytic vectors). A pioneer in gene delivery technologies, GTI is focused on developing breakthrough solutions for the healthcare area considered most promising to gene therapy -- cancer. GTI holds a leading position in oncolytic vectors, viruses that selectively kills cancer cells, offering the prospect of effectively treating a wide range of cancers at increased safety and lower toxicity to patients. Complementing the emphasis on oncolytic vectors, GTI is also exploring gene therapies that attack tumors by inhibiting their blood supply, also known as anti-angiogenesis.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
500+
Revenue Range
Over 50M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : GTII
IP Holdings
15-19

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1995 1 NIH $97,730
Project Title: Targeting Adeno Vectors by Fiber Protein Engineering
1995 1 NIH $99,982
Project Title: Upregulaton of HSV TK Gene & Brain Cancer Gene Therapy
1994 2 NIH $550,000
Project Title: Retroviral vectors to express Alpha-IFN in human TIL
1993 2 NIH $549,791
Project Title: Generation and study of IL-1 secreting TIL cells
1990 1 NIH $48,760
Project Title: Liver growth factor gene cloning and expression

Key People / Management

  Mike Perry -- President

  Yung-Nien Chang

  Yawen L Chiang

  Alan McClelland

  Robert C Moen

  Paul Tolstoshev

Company News

There are no news available.